Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Core Viewpoint - Clearmind Medicine Inc. has submitted an additional patent application to the USPTO as part of its collaboration with SciSparc Ltd. to develop novel psychedelic-derived therapeutics aimed at addressing under-treated health issues, including obesity and addiction [1][3][4]. Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to tackle significant health problems, particularly alcohol use disorder [4]. - The company currently holds an intellectual property portfolio consisting of eighteen patent families, including 28 granted patents, and aims to expand its patent holdings opportunistically [10]. Collaboration and Patent Applications - In collaboration with SciSparc, Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including the combination of SciSparc's PEA and Clearmind's MEAI compound for treating alcohol use disorder, cocaine addiction, and obesity [3][8]. - The latest patent application specifically refers to the proprietary composition of Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for addressing metabolic syndrome and obesity [8]. Market Context - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a rapid revenue CAGR of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [9].